Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06224673 · ClinicalTrials.gov registry record · Phase 2
ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer
A Phase 2 study, sponsored by Laura Huppert, MD, BA.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT06224673 is a Phase 2 study that is actively recruiting participants, run by Laura Huppert, MD, BA. The registered enrollment target is 36 participants.
The verdict
NCT06224673, a Phase 2 study, is actively recruiting participants, sponsored by Laura Huppert, MD, BA.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are naturally produced by the body's immune system to help fight infections. ARX788 consists of antibodies that have been attached to a toxin that has the potential to kill cancer cells. ARX788 sticks to a protein called human epidermal growth factor receptor (HER2), which is found on some breast cancer cells. Giving ARX788 may be safe and effective in treating patients with HER2-low locally advanced unresectable metastatic breast cancer.
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Computed Tomography (CT)
- DRUG Amiloride
- DRUG ARX788
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2026-06-05 |
| Est. Completion | 2029-11-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06224673
The ClinicalTrials.gov registry entry for NCT06224673 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Laura Huppert, MD, BA, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT06224673 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06224673 about?
NCT06224673 is a clinical study titled "ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer". This phase II trial tests how well ARX788 works in treating patients diagnosed with HER2-low, locally advanced unresectable or metastatic breast cancer. ARX788 is an antibody-drug conjugate (ADC) that is given by infusion (diluted and injected slowly into veins). Antibodies are proteins which are na...
What is the current status of trial NCT06224673?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2026-06-05. Estimated completion is 2029-11-30.
What interventions are being tested in trial NCT06224673?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Computed Tomography (CT) (PROCEDURE), Amiloride (DRUG), ARX788 (DRUG).
Who is sponsoring clinical trial NCT06224673?
This trial is sponsored by Laura Huppert, MD, BA, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.